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Second-line treatments recommended by the National Cancer Center Network to manage advanced-stage gastrointestinal stromal
tumours (GIST) were evaluated to determine the cost and cost-effectiveness of each intervention in the Mexican insurance system,
the Instituto Mexicano del Seguro Social (IMSS). Treatments examined over a 5-year temporal horizon to estimate long-term costs
included 800mgday
 1 of imatinib mesylate, 50mgday
 1 of sunitinib malate (administered in a 4 week on/2 week rest schedule), and
palliative care. The mean cost (MC), cost-effectiveness, and benefit of each intervention were compared to determine the best GIST
treatment from the institutional perspective of the IMSS. As sunitinib was not reimbursed at the time of the study, a Markov model
and sensitivity analysis were conducted to predict the MC and likelihood of reimbursement. Patients taking 800mgday
 1 of imatinib
had the highest MC (±s.d.) of treatment at $35225.61 USD (±1253.65 USD); while sunitinib incurred a median MC of $17805.87
USD (±694.83 USD); and palliative care had the least MC over treatment duration as the cost was $2071.86 USD (±472.88 USD).
In comparison to palliative care, sunitinib is cost-effective for 38.9% of patients; however, sunitinib delivered the greatest survival
benefit as 5.64 progression-free months (PFM) and 1.4 life-years gained (LYG) were obtained in the economic model. Conversely,
patients on imatinib and palliative care saw a lower PFM of 5.28 months and 2.58 months and also fewer LYG (only 1.31 and 1.08
years, respectively). Therefore, economic modeling predicts that reimbursing sunitinib over high dose imatinib in the second-line GIST
indication would deliver cost savings to the IMSS and greater survival benefits to patients.
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Gastrointestinal stromal tumours (GISTs) are rare in the Mexican
population (Alvarado-Cabrero et al, 2007); nonetheless, this
tumour type is expensive to treat as many patients are diagnosed
in the advanced and thus more costly stages of disease. Multiple
treatment options for second-line GIST exist; yet interventions
have not been investigated from the cost and cost-effectiveness
perspective of the major payer for oncology treatment in Mexico,
the Instituto Mexicano del Seguro Social (IMSS). This is a new
predicament as prior to 2001 the only treatment for GIST beside
surgical resection was palliative care (Dematteo et al, 2002). In fact,
no intervention for patients with advanced non-resectable tumours
or disease progression had been identified (Emory et al, 1999).
However, the discovery that abnormalities in the KIT tyrosine
kinase receptor had impact on tumour development led to the
creation of targeted GIST therapies (Dematteo et al, 2002; Fletcher
et al, 2002; Hassan et al, 2006; Hirota and Isozaki, 2006; Miettinen
et al, 2006; Hornick and Fletcher, 2007). In 2004, imatinib was
approved for use as a first-line treatment for GIST after phase II
and III clinical trials yielded overall response rates of approxi-
mately 50%, a 1-year survival rate greater than 80%, and a 2-year
survival rate around 70% (Joensuu et al, 2001; Dagher et al, 2002;
Demetri et al, 2002, 2005; Verweij et al, 2004). While imatinib is a
promising treatment option for many GIST patients other
treatments need to be evaluated for reimbursement as 12–14%
of patients show primary resistance; 40% develop secondary
resistance after 25 months; and an additional 5% of patients
become imatinib intolerant and discontinue therapy (Blanke and
Corless, 2005; Van Glabbeke et al, 2005). Since the 400mg dose of
imatinib is ineffective in a growing number of advanced GIST
patients, alternative therapy options are important in GIST
treatment and disease management.
As the cost and cost-effectiveness of second-line GIST treatment
has not been thoroughly investigated; reimbursement agencies like
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sthe IMSS do not have cost and benefit data specific to different
GIST therapies. Given the growing cost of therapy and the
increasing dependence on the IMSS to cover treatment, a
pharmaco-economic analysis was conducted to determine which
therapy option would deliver the greatest benefit at the lowest cost
to the institution. While pharmaco-economic analyses are limited
to the country they are conducted in; such research is helpful to
understand the cost-benefit of comparative therapies while
offering reimbursement insight to similar National Health
Systems. The three second-line treatment alternatives recom-
mended by the National Cancer Center Network (NCCN) were
compared to determine the best therapy for reimbursement. These
treatments included: (1) increasing the imatinib dosage (to
800mgday
 1); (2) switching to sunitinib (50mgday
 1 on a
4-week on/2 week off treatment schedule); or (3) regulating
symptoms with palliative care. Because GIST is associated with
long-term therapy, the cost of treatment per patient was calculated
over the duration of therapy to determine a total cost. Direct
medical costs and reimbursed therapies associated with second-
line GIST treatment were factored into cost calculations to derive
an overall mean cost (MC) for each treatment. However, a Markov
model was created to determine the MC of sunitinib as at the time
of analysis sunitinib was not reimbursed in Mexico. Adverse event
and survival rates from the pivotal sunitinib study by Motzer et al
(2006) and the Demetri et al (2006) survival study were used to
construct the model. Hypothetical IMSS reimbursement values
were calculated to evaluate therapy cost. The reimbursement of
GIST was based on the values set by the National Institute of
Clinical Excellence (NICE) to determine the cost-effectiveness of
sunitinib as compared to palliative therapy by utilising 5, 14, and
40% cuts of the highest NICE reimbursement level. Because
increased morbidity and mortality is associated with advanced
GIST, incremental cost-effectiveness ratios (ICERs), life years
gained (LYG) and progression free months (PFM) were evaluated
to obtain the survival gain for each therapy.
MATERIALS AND METHODS
To estimate the cost and cost-effectiveness of second-line
treatment this observational study collected imatinib and palliative
care costs; created a Markov model, and conducted a sensitivity
analysis. The investigation was conducted to determine the total
cost an intervention would incur the IMSS per patient over the
entire duration of second-line GIST treatment. Treatment costs
were collected from the start of treatment until the documentation
of tumour progression (Park et al, 2003; Watanabe et al, 2003).
Further, patient data was investigated for a maximum of 5 years
(referred to as the 5-year temporal horizon) so MC would be a true
cost estimate of GIST care with a specific treatment. Cost-
effectiveness measures were also an integral part of the analysis
and were determined by using the ICER (see equation below).
Specifically, LYG and PFM were calculated to determine the cost-
effectiveness of each therapy.
ICER ¼
CostsA   CostsB
EffectA   EffectB
Primary data sources: imatinib, palliative care and
standard procedures
All patients (N¼21) receiving second-line treatment for advanced
GIST from 1 January 2005 to 31 December 2007 at the Hospital de
Oncologı ´a were analysed to estimate the cost of care associated
with imatinib, palliative care, and standard oncology procedures in
Mexico. The clinical data, demographic characteristics, and
medical procedures of patients receiving care for advanced GIST
were obtained from patient medical charts to estimate the total
cost associated with each procedure for the IMSS (see Table 1).
Specifically, the mean number of visits to the oncologist,
laboratory exams, radiology studies, and length of hospital stay
were counted and quantified with the cost the IMSS would incur.
Since data collection was dependent on medical charts, patients
with insufficient information in their medical charts were
excluded. Also, as the intent of this model was to characterise
the MC associated in advanced GIST patients, subjects with two or
more cancer types were also excluded.
Second-line therapeutic alternatives were chosen based on
NCCN guidelines. Treatment alternatives evaluated in this analysis
were appropriate for patients with GIST diagnosis that had non-
resectable disease, widespread metastatic disease, or displayed
imatinib treatment failure. To be in accordance with guidelines,
the analysis estimated the cost and cost-effectiveness associated
with: (1) the dosage increase of imatinib (800mgday
 1); (2) the
use of sunitinib (50mgday
 1 administered for 4 weeks with 2 week
rest); and (3) the administration of palliative care (National
Comprehensive Cancer Network, 2006). Please note that palliative
care is not always provided exclusively; instead palliative care (or
rather supportive care) is often combined with imatinib or
sunitinib to improve symptoms and social support. Further, since
supportive care was administered with imatinib at Hospital de
Oncologı ´a and is covered by the IMSS, supportive treatments are
included in therapy MC estimates.
Markov model
The Markov model (see Figures 1–3) utilised results from the
pivotal sunitinib phase III study by Motzer et al (2006) and a
Table 1 Characteristics of 21 advanced gastrointestinal stromal tumor
(GIST) patients who were treated at the Hospital de Oncologı ´a, IMSS
Patient data
Characteristic n¼21
Age (years)
Mean (s.d.) 56.4 (12.9)
Sex, no (%)
Female 17 (81)
Male 4 (19)
Tumour localisation, n (%)
Stomach 13 (16.9)
Small bowel 4 (19.0)
Rectum 4 (19.0)
Metastatic disease, n (%)
Liver 14 (66.7)
Colon 2 (9.5)
Follow-up period (months)
Mean (s.d.) 26.19 (20.9)
Range 6–73
No of oncologist visits per patient
Mean (s.d.) 27.0 (15.2)
Range 9–68
No of laboratory exams per patient
Mean (s.d.) 188.0 (13.71)
No of radiology studies per patient
Mean (s.d.) 16.46 (4.0)
Hospital length stay per patient (days)
Mean (s.d.) 7.0 (9.5)
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ssurvival study by Demetri et al (2006) to ascertain the cost and
cost-effectiveness associated with taking the approved 50mgday
 1
of sunitinib in a 4 week with 2 week rest treatment schedule.
Specifically, the 54-week follow-up data of the Motzer et al (2006)
study were extrapolated to calculate the survival time of patients
taking sunitinib. As this trial was conducted in patients who had
previously taken 400mgday
 1 of imatinib, data used in the model
was representative of second-line GIST patients. Kaplan–Meier
survival curves and survival tables from the Demetri et al (2006)
study were applied to the model as this analysis followed patients
to the sixth year of treatment. Six-week cyclic intervals were
incorporated into the model to identify the progression of disease
or any adverse events that potentially would increase or decrease
sunitinib treatment cost. All costs, with the exception of sunitinib,
used in the model are based on IMSS pricing and reimbursement
procedures. Because sunitinib was not available in the Mexican
market at the time of the analysis its cost information was
provided by Pfizer Laboratories.
Economic analysis
A 5% discount rate was applied to predict the cost and benefit of
each GIST treatment (Smith and Gravelle, 2000). Application of
this rate allowed a current assessment of all costs associated with a
specific therapy while also capturing the cost-effectiveness of each
intervention. All input prices and cost outputs were in Mexican
pesos; prices were converted to US dollars (assuming 11.00 pesos
per dollar exchange rate) after the analysis. Specifically, the ‘Case
Mix’ methodology was used to generate cost.
Statistical analysis
SPSS version 12.0 statistical software was used throughout the
analysis. Weibull curves were estimated and then used to
extrapolate the survival information over the 5-year period. The
Weibull curve probability function was characterised by two
parameters, lambda (l) and gamma (j), as expressed in the
following formula:
fðtÞ¼lgtg 1 expð ltgÞ:
The survival function is expressed by:
SðtÞ¼expð ltgÞ:
The lambda and gamma parameters, as well as s.d. and correlation
coefficients were estimated (see Table 2) according to the Demetri
et al (2006) study.
Sensitivity analysis
The sensitivity analysis was conducted with data obtained from the
Markov model. Hypothetical values were investigated at three time
points during treatment, 1, 3 and 5 years specifically. In this
probabilistic-type sensitivity analysis, the model was run one
thousand times to evaluate robustness. Acceptability curves were
also built and simulated to identify cost-effectiveness ratios for
sunitinib in comparison to palliative care. As the local thresholds
of cancer therapy cost have not been determined in Mexico, each
curve was based on the different levels of payment, which IMSS
would hypothetically contain ($27273 USD, $36364 USD, and
$45455 USD). Hypothetical values were based on the reimburse-
ment of first-line treatment with imatinib set by the National
Institute of Clinical Excellence (NICE) in the UK. These simula-
tions assumed a b distribution for utility and a g distribution for
costs imputed by the model. As the b utility were between 0 and 1,
and since g values are both non negative and not normally
distributed; it can be assumed that treatment costs in the model
were representative of real world expenditures.
Sunitinib treatment
(no progression)  
Palliative care  
(progression)
Death
High dose of imatinib 
(800 mg day–1)
Palliative care 
(progression)
Death
Palliative care(with/
without progression)
Death
Figure 1 (A) Markov model considering sunitinib malate treatment. (B)
Markov model considering high doses of imatinib treatment. (C) Markov
model considering the palliative treatment.
5.64
2.58
5.28
01 234 56
Sunitinib maleate
Better supportive
treatment
Imatinib 800 mg day–1
Progression-free months
Figure 2 Disease progression-free months comparison, according to
each therapeutic alternative, after 5 years.
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Patient demographic and clinical data
Based on information from patient medical charts, the mean
patient age was 56.4 years. Thirteen patients had localised tumours
in the stomach, four had localised bowel tumours, and four had a
localised tumour in the rectum. Further, 14 of the 21 patients
(66.7%) had metastatic liver disease and two had metastasis in the
colon (Table 1).
Medical cost data
The mean treatment follow up period of the sample was 26.2
months, during this time period the mean number of visits to the
oncologist, laboratory exams, and radiology procedures were 27.0,
188.1 and 16.5 events. In addition, the mean length of hospital stay
was 7.0 days per patient. Using IMSS cost data, patients treated in
the sample had an annual MC per patient for medical consulta-
tions, hospitalizations, laboratory examinations, and radiology
procedures of $2424.32 USD, $2657.57 USD, $566.99 USD, and
$2392.67 USD, respectively. The highest annual MC per patient on
drug therapy was $38621.09 USD for a patient on imatinib. Results
from the model (see Table 3) demonstrated that the highest MC
(þs.d.) expected per patient over the treatment horizon was also
in individuals taking high dose imatinib (800mgday
 1, treatment
cost equivalent to $35225.61±1253.65 USD); followed by patients
taking sunitinib (50mgday
 1 on a 4 week on/2 week off treatment
schedule, treatment cost equivalent to $17805.87±694.83 USD);
and was the lowest in patients receiving palliative care
($2071.86±472.88 USD). When the model compared the cost of
sunitinib to palliative care, the ICER per patient treated with
sunitinib was $15734.23 USD.
Cost-effectiveness analysis
Sunitinib yielded a higher number of disease PFM than both
imatinib and palliative care therapies (see Figure 4). Over the
treatment horizon, sunitinib showed a mean PFM of 5.64, while
imatinib and palliative care yielded smaller gains of 5.28 and 2.58
1.40
1.08
1.31
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60
Sunitinib maleate
Better supportive
treatment
Imatinib 800 mg day–1
Life-year gained
Life-year saved
Sunitinib
 malate
Best
supportive
 care
Imatinib 800
 mg day–1
Mean 1.40 1.08 1.31
S.d. 0.1 0.1 0.0
95% confidence interval - low 1.3 1.0 1.2
95% confidence interval - high 1.6 1.3 1.4
Figure 3 Life-year gained comparison, according to each therapeutic alternative after 5 years.
Table 2 Parameters used to build survival Weibull curves
Lambda
a Gamma
a Correlation coefficients R
2b
Total survival: best supportive care 0.013641 (0.002600) 1.06418 (0.06225)  0.98360 0.94424
Total survival: sunitinib
c 0.002183 (0.000551) 1.40080 (0.07333)  0.9940 0.96441
Free progression survival: best supportive care 0.039030 (0.009569) 1.49029 (0.11946)  0.9803 0.92923
Free progression survival: sunitinib 0.042038 (0.006473) 0.94287 (0.05051)  0.9774 0.93136
aMean and s.d.
bR
2 describes the model explanation capacity with the original data (e.g. when the estimation is closer to 1.0, the survival curves have a better explanation
capacity).
cThe utility levels for each stratum are the same for high doses of imatinib.
Table 3 Total costs expected per patient (US dollars, 2006)
Costs Sunitinib
Best supportive
care
High doses
imatinib
Mean $17805.87 $2071.86 $35225.61
s.d. $694.83 $472.88 $1253.65
Low 95% confidence
interval
$15377.23 $1543.32 $31381.21
High 95% confidence
interval
$19815.68 $2869.36 $38705.18
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palliative care was 3.1 PFM with sunitinib and 0.3 PFM with high
dose imatinib.
Patients that took sunitinib also gained more life-years than
patients on other second-line treatments (Figure 5). Over the
5-year treatment horizon LYG for patients on sunitinib, imatinib
and palliative care were 1.40, 1.31, and 1.08, respectively.
Incrementally, sunitinib data yields a 0.32 LYG when compared
to palliative treatment. Mean cost-effectiveness and ICERs among
the treatment alternatives for advanced GIST over a 5-year
treatment horizon are shown in Table 4.
Sensitivity analysis
The upper threshold recommended by NICE (d25000 or about
$51300 USD) was used for the probabilistic-type sensitivity
analysis since the oncology funds available by the IMSS have yet
to be determined (Wilson et al, 2005). A hypothetical cohort of
1000 patients taking either sunitinib or seeking palliative care was
constructed to demonstrate how the cost-effectiveness of therapy
changes as the cost for intervention increases. The majority of
patients are located above the best fit line, and therefore the
analysis predicts that the most cost-effective treatment for the
majority of patients would be palliative care. Only the 38.9% of
patients located below the cost threshold are predicted to receive
greater cost-benefit from second-line treatment with sunitinib.
However, the sensitivity analysis also predicted that the majority
of patients would receive greater benefit from taking sunitinib
than palliative care as patients taking sunitinib see greater
increases in LYG.
Results from the sensitivity analysis were used to develop the
acceptability curve for second-line treatment with sunitinib. The
approximate amount of money the IMSS is willing to pay for an
intervention was based on the proportion of cost-effectiveness
gained by that treatment. As reimbursement for oncology
compounds is unknown in Mexico, hypothetical reimbursement
of the cut points in USD were $27272.72, $36363.63, and
$45454.54; values were derived by taking 5, 14 and 40% of the
upper threshold that NICE reimburses for imatinib. The IMSS is
predicted to pay more for a second-line therapy if it demonstrates
a higher cost-effectiveness ratio than comparators. The cost-
effectiveness of treatment with sunitinib was evaluated at 1, 3, and
5 years and the ICER was found to change the least during the first
year. Patients that began treatment with palliative care saw little
difference in LYG than patients on sunitinib; however, the cost
difference is great. Yet, regardless of treatment type, the majority
(490%) of patients with advanced GIST die after the third year of
treatment; and therefore smaller cost is incurred by the IMSS at
year three regardless of therapy.
DISCUSSION
Research has deepened scientist’s understanding of the etiology of
cancer and today multiple therapies exist to treat advanced GIST.
Because patients and doctors are no longer reliant on palliative
care for the second-line treatment of advanced GIST, it is
important to determine which therapies provide the most benefit
as GIST patients face serious survival and quality of life issues
(Perez et al, 2006). Yet, GIST treatment is expensive and cost has
become an important aspect of treatment as the budgets of many
public medical payers are constrained. The aim of this analysis was
to evaluate the cost, cost-effectiveness, and benefit associated with
imatinib, sunitinib, and palliative treatment to ascertain the best
second-line therapy option from the standpoint of the national
health payer in Mexico, the IMSS.
It’s important to underline that no randomised trial data of high
dose imatinib vs 50mgday
 1 of sunitinib (in a 4 weeks on/2 weeks
off treatment schedule) is available, and currently such work is just
beginning. Therefore, economic modeling is a mechanism that can
be used to predict trends in the absence of real data. The
800mgday
 1 dose of imatinib and the 50mgday
 1 dose of
sunitinib were chosen for investigation because the medical
literature has shown that: (1) patient survival improves as the
imatinib dose increases (Blay et al, 2005); and that (2) taking
sunitinib results in increased effectiveness and survival over
imatinib (Demetri et al, 2006). PFM was calculated for all therapies
over the five-year treatment duration to determine the impact of
therapy on patient survival. As Figure 4 shows, PFM increases
when patients receive therapy for second-line GIST; however, PFM
increase is different among treatment types. Sunitinib delivered the
greatest survival benefit as the regimen stopped disease progres-
sion for 5.64 months; while high dose imatinib delayed disease
progression for 5.28 months; and palliative care prevented
progression for 2.58 months.
Sunitinib malate vs supportive treatment (comparator)
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Figure 4 Probabilistic sensitivity analysis for sunitinib malate vs palliative
care.
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Figure 5 Acceptability curve for sunitinib malate vs palliative care (US
dollars).
Table 4 Cost-effectiveness (mean and incremental) with the three
treatment alternatives, 5-year horizon
CER CER ICER ICER
Alternative
Years of free
survival
progression
Years
gained
Years of free
survival
progression
Years
gained
Sunitinib 35057.22 11862.35 — —
Palliative care 8869.06 1754.80 56612.55 46108.89
High doses
imatinib
84540.50 28423.57 Dominated Dominated
CER: Cost-effectiveness ratio (mean); ICER: Incremental cost-effectiveness ratio.
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treatment. Patterns of resource use and medical procedures were
also identified to cover the MC of GIST care. Costs associated with
treatment such as hospital stay, laboratory testing, visits to the
oncologist, and supportive care were calculated into the MC to
capture all expenditures associated with a treatment. The most
expensive treatment alternative was high dose imatinib as patients
experienced an MC of $35225.61, while the cheapest alternative
was palliative care as patients had an MC of $2071.86.
Alternatively, the model predicted that treatment with sunitinib
would yield a median of MC of $17805.87.
Few studies have evaluated GIST treatment and even fewer have
examined possible second-line treatment alternatives from a cost-
effectiveness standpoint Rubin et al, 2007. Case in point, the
literature supports the recommendation to increase the dosage of
imatinib to 800mgday
 1 after first-line treatment failure (Demetri
et al, 2006) even though the elevated dosage has yet to be
compared with other second-line GIST treatments. Hopefully,
more therapeutic and economic comparisons will be conducted to
determine the best treatment for GIST, as to date the only other
economic evaluation has been conducted. This evaluation by NICE
on the first-line treatment of imatinib found it to be a cost-effective
GIST treatment. Since no data is available to determine the
reimbursement of cancer therapies by the IMSS, the upper
reimbursement threshold recommended by NICE (d25000 or
about $51300 USD) was used to conduct the sensitivity analysis.
When sunitinib was compared to palliative care, only 38.9% of
patients are expected to receive greater cost-benefit from sunitinib.
Even though the sensitivity analysis showed high variability from
the actual ICER; the results obtained from the model support, the
inclusion of sunitinib as a reimbursable therapy to manage GIST.
Because GIST patients tend to have lower life expectancies, the
model favours cheaper palliative care as the best solution. It is
difficult to put a price on life, therefore the effectiveness and
benefit measures should be given more weight in GIST studies
Badalamenti et al, 2007. As Figure 4 shows, the majority of patients
would experience greater LYG on sunitinib than on palliative care.
Further, when LYG was compared among therapies the model
predicted that patients taking sunitinib would experience greater
LYG than patients taking imatinib or palliative care (see Figure 5).
Acceptability curves for sunitinib were constructed to predict the
reimbursement of GIST treatment by the IMSS. As the curves
showed low percentages with different cut-points for willingness to
pay (Figure 5), alleviating unnecessary costs to save on overall
treatment will be key.
In closing, the weaknesses of the analysis should be discussed.
First, the generalizability of the study is compromised as a
mathematical model was used to predict the cost, cost-effective-
ness, and benefit for the three treatment alternatives (imatinib,
sunitinib and palliative care). Different outcomes occur in subjects
that undergo the same procedure, and unfortunately a model
cannot capture or predict all results. Second, as GIST is a rare
disease and current treatment had to be obtained from a sample of
21 mostly female patients; it is possible that imatinib and palliative
care data may not be representative of all patients on second-line
GIST treatment in Mexico. However, as all eligible patients were
analysed and as GIST has no sex-specific implications, the sample
should be representative. Nonetheless, in the future we hope to
validate the model and amend these issues by using real patient
data and a large patient database. Lastly, this analysis cannot
predict how cost and benefits would change if the dose or
administration of sunitinib changed; therefore the analysis is
limited to describing the reimbursement, cost, and benefits of
patients taking the 37.5mgday
 1 dose of sunitinib in a 4 week on/2
week off treatment schedule.
Conclusion
The model predicts that 50mgday
 1 of sunitinib administered in a
4-week with 2 week rest treatment schedule would be the most
cost-effective option in second-line treatment. Therefore, the IMSS
would not only observe major savings by reimbursing sunitinib,
but also would provide patients with access to a new therapy with
the greatest survival benefits in second-line GIST.
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